Oxford Gene Technology, a provider of clinical genetics and diagnostic solutions to advance molecular medicine, has expanded its CytoSure product range to include high-throughput genomic DNA labelling kits and sample tracking spike-ins.
With the release of EASYLABEL 5 Platinum, Tharo Systems, Inc. is providing a collection of tools for FDA 21 CFR Part 11 compliance, including additional password and user options, logging options and format options.
A study has unveiled a surprising mechanism that controls brain formation. The findings have implications for understanding a host of diseases, including some forms of mental retardation, epilepsy, schizophrenia, and autism.
Teva Pharmaceutical Industries Ltd., the world's biggest maker of generic drugs, said its profit more than doubled in the fourth quarter as the company expanded its European business and sales of its multiple sclerosis drug Copaxone improved.
GenoLogics announced it has signed a worldwide co-selling agreement with Illumina, Inc. Under terms of the deal, Illumina will market a version of the Geneus LIMS that is pre-configured for Illumina’s NGS instruments and TruSeq sample preparation kits.
CeNeRx is now preparing to launch further Phase 1 studies of CXB909 targeting chemotherapy-induced peripheral neuropathy as its first potential indication. CXB909 is believed to promote synthesis of acetylcholine.
PolyMedix, Inc. has initiated a Phase 2 clinical trial to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing percutaneous coronary intervention procedures.
Successful intranasal delivery of stem cells to the brains of rats with Parkinson disease yielded significant improvement in motor function and reversed the dopamine deficiency characteristic of the disease.
Researchers are reporting on a promising new approach to treating diabetic wounds, bed sores, chronic ulcers and other slow-to-heal wounds. It may be possible to speed healing by suppressing certain immune system cells.
Researchers have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes. The discovery could help speed the development of peptide-based drugs against diseases including cancer.
The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease. Investigators found that the annual cost of $1,400 is impractical when compared to the marginal impact on survival and quality of life.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved an update to the labeling for REYATAZ to include dose recommendations in HIV-infected pregnant women.
Teva Pharmaceutical Industries Ltd. said its allergy drug Qnaze met its goal in a late-stage study that tested its ability to treat year-round allergies. Teva said the clinical trial showed Qnaze was more effective than a placebo at treating nasal allergy symptoms.
Federal health officials are proposing a plan that would speed up the approval of innovative medical devices that have the potential to dramatically improve patients' lives.
Sanofi-Aventis said that hefty new restructuring costs caused its net profit to slump 64 percent in the fourth quarter, amid continued uncertainty over the fate of its nearly $20 billion bid for U.S. biotechnology firm Genzyme Corp.